Evidence map›Paper›PMID 37878214›Full record

ReviewHuman cell2024

Prospects of plant-derived exosome-like nanocarriers in oncology and tissue engineering.

Shima Rahmati, Hafez Karimi, Morteza Alizadeh, Amir Hossein Khazaei, Ana Cláudia Paiva-Santos, Leila Rezakhani, Esmaeel Sharifi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Human cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Therapeutic potential of garlic-derived exosome like nanovesicles: challenge and opportunity.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Application of exosomes in tumor immunity: recent progresses.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Shima RahmatiCancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Hafez KarimiStudent Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Morteza AlizadehDepartment of Tissue Engineering, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Amir Hossein KhazaeiStudent Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ana Cláudia Paiva-SantosDepartment of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal.
Leila RezakhaniFertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Leila_rezakhani@yahoo.com.
Esmaeel SharifiCancer Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. esmaeel.sharifi@gmail.com.
Kermanshah University of Medical Sciences · IRHamedan University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRShahrekord University of Medical Sciences · IRShahroud University of Medical Sciences · IRUniversity of Coimbra · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Almost all cell types, either in vivo or in vitro, create extracellular vesicles (EVs). Among them are exosomes (EXOs), i.e., tiny nanovesicles containing a lipid bilayer, proteins, and RNAs that are actively involved in cellular communication, indicating that they may be exploited as both diagnostics and therapeutics for conditions like cancer. These nanoparticles can also be used as nanocarriers in many types of research to carry agents such as drugs. Plant-derived exosome-like nanoparticles (PENs) are currently under investigation as a substitute for EXOs formed from mammalian cells, allowing researchers to get beyond the technical constraints of mammalian vesicles. Because of their physiological, chemical, and biological properties, PENs have a lot of promise for use as nanocarriers in drug delivery systems that can deliver various dosages, especially when it comes to large-scale repeatability. The present study has looked at the origins and isolation techniques of PENs, their anticancer properties, their usage as nanocarriers in the treatment of different illnesses, and their antioxidant properties. These nanoparticles can aid in the achievement of therapeutic objectives, as they have benign, non-immunogenic side effects and can pass biological barriers. Time-consuming and perhaps damaging PEN separation techniques is used. For the current PEN separation techniques to be used in commercial and therapeutic settings, they must be altered. In this regard, the concurrent application of biological sciences can be beneficial for improving PEN separation techniques. PENs' innate metabolic properties provide them a great deal of promise for application in drug delivery systems. However, there could be a risk to both the loaded medications and the intrinsic bioactive components if these particles are heavily armed with drugs. Therefore, to prevent these side effects, more studies are needed to devise sophisticated drug-loading procedures and to learn more about the physiology of PENs.

Indexed as

ExosomesExtracellular VesiclesNeoplasmsAnimalsDrug Delivery SystemsMammalsTissue EngineeringCancerExosomeNanoparticlePlantRegeneration medicine

Identifiers

PMID37878214
OpenAlexW4387931425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.